Home › Funds › SILVERARC CAPITAL MANAGEMENT, LLC › RYTM
SILVERARC CAPITAL MANAGEMENT, LLC position in RYTM
RHYTHM PHARMACEUTICALS INC · Health Care
SILVERARC CAPITAL MANAGEMENT, LLC reported holding 348,317 shares of RYTM (RHYTHM PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$33.2M, representing 4.23% of its reported portfolio and ranking #8 among its reported holdings. SILVERARC CAPITAL MANAGEMENT, LLC has disclosed RYTM holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How SILVERARC CAPITAL MANAGEMENT, LLC's RYTM position evolved
SILVERARC CAPITAL MANAGEMENT, LLC first disclosed a stake in RYTM in Q3 2023 at 260,537 shares (US$6.0M). The position peaked in Q3 2025 at 369,996 shares, worth US$37.4M. Across 13 filings, SILVERARC CAPITAL MANAGEMENT, LLC increased the stake 8 time(s), trimmed it 3 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 348,317 shares valued at US$33.2M — an increase of 36,856 shares quarter over quarter.. Notable position changes include a 38% increase in Q3 2024 (shares rose 7% over the following quarter), a 63% trim in Q4 2025 (shares fell 19% over the following quarter), a 125% increase in Q1 2026 (shares rose 28% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 260.54K | $5.97M | New |
| Q4 2023 | 174.25K | $8.01M | Reduce |
| Q1 2024 | 183.78K | $7.96M | Add |
| Q2 2024 | 184.66K | $7.58M | Hold |
| Q3 2024 | 255.58K | $13.39M | Add |
| Q4 2024 | 273.90K | $15.33M | Add |
| Q1 2025 | 337.61K | $17.88M | Add |
| Q2 2025 | 400.77K | $25.32M | Add |
| Q3 2025 | 370.00K | $37.37M | Reduce |
| Q4 2025 | 135.95K | $14.55M | Reduce |
| Q1 2026 | 306.00K | $26.61M | Add |
| Q2 2026 | 311.46K | $34.58M | Add |
| Q3 2026 | 348.32K | $33.17M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About RYTM and 13F data
RYTM (RHYTHM PHARMACEUTICALS INC) is a Health Care company. 43 other funds we track also report a position in RYTM — the largest reported positions include RA CAPITAL MANAGEMENT, L.P. (US$740.2M), BAKER BROS. ADVISORS LP (US$622.3M), PERCEPTIVE ADVISORS LLC (US$287.2M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding RYTM
- RA CAPITAL MANAGEMENT, L.P. 6.67M sh · $740.22M · Q2 2026
- BAKER BROS. ADVISORS LP 5.60M sh · $622.27M · Q2 2026
- PERCEPTIVE ADVISORS LLC 2.59M sh · $287.16M · Q2 2026
- WESTFIELD CAPITAL MANAGEMENT CO LP 2.48M sh · $236.20M · Q3 2026
- Polar Capital Holdings Plc 1.66M sh · $184.71M · Q2 2026
- Checkpoint Capital L.P. 1.19M sh · $131.68M · Q2 2026
- Siren, L.L.C. 1.09M sh · $103.43M · Q3 2026
- Rock Springs Capital Management LP 692.60K sh · $76.90M · Q2 2026
- Integral Health Asset Management, LLC 550.00K sh · $61.07M · Q2 2026
- Sofinnova Investments, Inc. 408.03K sh · $45.30M · Q2 2026
More on SILVERARC CAPITAL MANAGEMENT, LLC
FAQ
How long has SILVERARC CAPITAL MANAGEMENT, LLC held RYTM?
SILVERARC CAPITAL MANAGEMENT, LLC has disclosed RYTM holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is SILVERARC CAPITAL MANAGEMENT, LLC's current position in RYTM?
As of Q3 2026, SILVERARC CAPITAL MANAGEMENT, LLC holds 348.32K shares of RYTM (RHYTHM PHARMACEUTICALS INC), valued at $33.17M, representing 4.23% of its reported portfolio and ranking #8.
Has SILVERARC CAPITAL MANAGEMENT, LLC been buying or selling RYTM?
In the latest 13F filing (Q3 2026), SILVERARC CAPITAL MANAGEMENT, LLC increased its position in RYTM. The position peaked in Q3 2025 at 370.00K shares.
Which other funds hold RYTM?
Other major institutional holders of RYTM include RA CAPITAL MANAGEMENT, L.P., BAKER BROS. ADVISORS LP, PERCEPTIVE ADVISORS LLC, among 43 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.